A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer(Q1DX5/W for 3W).
Phase of Trial: Phase I
Latest Information Update: 05 May 2014
At a glance
- Drugs HM 30181A; Irinotecan
- Indications Solid tumours
- Focus Adverse reactions
- 05 May 2014 According to a Kinex media release, the US FDA has allowed the IND application for Oratecan.
- 05 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2009 New trial record